Simponi (golimumab) / Merck (MSD), Tanabe Pharma, J&J - LARVOL DELTA

Real-World Cardiovascular and Mortality Outcomes of Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis (ACR Convergence 2026) - "TNF inhibitors comprised adalimumab, etanercept, infliximab, certolizumab pegol, and golimumab. JAK inhibitors included tofacitinib, baricitinib, and upadacitinib... In this real-world study, Janus kinase inhibitors were associated with higher long-term mortality and a modest increase in major adverse cardiovascular events compared with tumor necrosis factor inhibitors, with notable differences across individual agents. These findings highlight the need for careful cardiovascular and thrombotic risk assessment when selecting JAK inhibitor therapy and support further prospective studies to refine patient selection."

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Venous Thromboembolism

Biomarker-Driven Insights From the Phase 2a AFFINITY Study Evaluating Guselkumab + Golimumab Combination Therapy Versus Guselkumab Monotherapy in Psoriatic Arthritis (ACR Convergence 2026) - P2 | "GUS+GOL CT was associated with significant reductions in CRP and IL-6 levels from BL. Pts with ACR50 and MDA responses to CT had higher BL levels of CRP and IL-6, and greater reductions in these inflammatory biomarkers over time, than nonresponders. These results support clinical findings that pts with TNFi-IR PsA may derive greater improvement in joint manifestations with GUS+GOL CT, especially in pts with elevated systemic inflammatory burden."

Biomarker • Combination therapy • Monotherapy • P2a data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL6

Comparative Outcomes in Pregnant Patients With Rheumatoid Arthritis Treated With and Without Tumour Necrosis Factor Inhibitors: A Systematic Review and Meta-Analysis. (ACR Convergence 2026) - "The most frequently used TNFi were adalimumab, certolizumab, and etanercept. Infliximab and golimumab were administered only to a minority of patients in 2 studies... To our knowledge, this is the first meta-analysis evaluating outcomes in pregnant patients exclusively with RA, treated with or without anti-TNF inhibitors. Amongst patients with RA, TNFi use in pregnancy does not appear to be associated with congenital anomalies, SGA, or preterm birth. This could help inform patient counselling around continuation of TNFi in the prenatal period in this patient population."

Retrospective data • Review • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Small for Gestational Age

Effectiveness of Guselkumab vs Golimumab in Participants with Active Psoriatic Arthritis and Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Interim Results at 6 Months in a Phase 3b, Randomized, Open-Label, Pragmatic Trial (ACR Convergence 2026) - No abstract available

Clinical • P3 data • P3 data: top line • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Advanced Therapies in IBD: Biologics and Beyond (IASGO 2026) - "Ulcerative colitis: For moderate-to-severe UC, biologic options include anti-TNF agents (infliximab, adalimumab,and golimumab), vedolizumab, ustekinumab, and selective IL-23 inhibitors (mirikizumab,risankizumab, and guselkumab). Small-molecule therapies, including JAK inhibitors (tofacitiniband upadacitinib) and S1P receptor modulators (ozanimod and etrasimod), further expandtherapeutic options...Recent AGA guidance further incorporates newer IL-23inhibitors, including mirikizumab and guselkumab, and upadacitinib into the expandingtherapeutic armamentarium. Overall, contemporary IBD management is shifting from rigid treatment algorithms toward early,individualized selection of advanced therapies, integrating efficacy, safety, disease phenotype, priortreatment exposure, and patient preference."

Metastases • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. (PubMed, RMD Open) - "ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies."

Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A

Rethinking First-Line Therapy: IL-23 Inhibitors vs Anti-TNF Agents in Biologic-Naive UC (ACG 2026) - "Eligible patients had a diagnosis of UC (ICD-10: K51.x) and were biologic naive at the time of cohort entry and initiated on anti-TNF agents (infliximab, adalimumab, or golimumab) or an IL-23 inhibitor (mirikizumab or risankizumab). After matching, 2,419 patients remained in each cohort. In fixed-time analysis excluding patients with prior outcome events, the composite outcome occurred in 39.35% of anti-TNF initiators versus 40.41% of IL-23 inhibitor initiators, with no significant risk difference (RR 0.974, 95% CI 0.789-1.201; OR 0.957, 95% CI 0.674-1.358; p=0.807). Kaplan-Meier analysis showed higher 1-year event-free survival among anti-TNF initiators (58.06% vs 47.42%; log-rank p=0.0048)."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Early Experience With Etrasimod in Ulcerative Colitis Patients: A Claims Database Study in the United States (ACG 2026) - "(e)Advanced treatments: adalimumab, golimumab, infliximab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, tofacitinib, upadacitinib, and ozanimod. A total of 297 patients were included (mean age, 47.3 years [SD, 17.5]; 52.2% male), and 127 comprised the follow-up population. In the follow-up population, most patients were AT-naïve (67.7%), and 48.0% had used steroids within 24 weeks prior to index date (Table 1). Through week 24, median adherence was 89.8% (quartile 1: 53.9%; quartile 3: 98.8%), and 59.1% of patients had PDC â¥0.80."

Claims database • Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Safety of Inadvertent Live Vaccine Administration in Patients With Inflammatory Bowel Disease on Immune-Modifying Therapy (ACG 2026) - "The exposed cohort comprised IBD patients who received a live vaccine (measles, mumps, and rubella (MMR), varicella, measles, mumps, rubella, and varicella (MMRV)...Inclusion required a vaccine CPT code, â¥12 months of continuous enrollment prior to index date, an IBD diagnosis (â¥2 IBD-related outpatient visits), and a prescription for an immune-modifying therapy (anti-tumor necrosis factor (TNF), vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab, guselkumab, or mirikizumab) < 90 days of the index date...³Anti-TNF agents: infliximab, adalimumab, certolizumab, golimumab...6Immunomodulators: methotrexate, azathioprine, 6-mercaptopurine... 220 IBD patients met inclusion criteria for the live vaccine cohort (132 MMR, 73 varicella, 15 MMRV); 170 (77%) were on anti-TNF therapy and 30 (14%) on vedolizumab (Figure). The comparator group comprised 2,204 PCV13 recipients Table for baseline demographics. All-cause hospitalization or ED..."

Clinical • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Measles • Mumps • Pneumococcal Infections • Rubella • Varicella Zoster • IL23A

Clinical and laboratory manifestations and treatment of children with TNFRSF1A gene variants. (PubMed, World J Clin Pediatr) - "Variants in the TNFRSF1A gene may cause a wide range of clinical symptoms, including eye and intestinal lesions that are not typical of sJIA. All patients with fever and unusual sJIA symptoms should have molecular genetic testing for TNFRSF1A variants to confirm or exclude AID early. Early diagnosis enables timely therapy and prevents complications. Tocilizumab (39.3%), canakinumab (33.3%), and TNF inhibitors (21.2%) achieved remission in children with TNFRSF1A variants. Some patients required multiple bDMARD switches to achieve remission, highlighting the complexity of treatment decisions in this group."

Journal • Amyloidosis • CNS Disorders • Gastrointestinal Disorder • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammation • Oncology • Otorhinolaryngology • Pain • Pediatrics • Rheumatology • Ventriculomegaly • TNFRSF1A

Biologic Therapy in Refractory Non-Infectious Uveitis: An Analysis of 60 Cases at a Tertiary Eye Care Centre from South India. (PubMed, Ocul Immunol Inflamm) - "Adalimumab was the most frequently used biologic agent (88.3%) followed by Infliximab (5%), golimumab (3.3%) and tocilizumab (3.3%). Biologic therapy is an effective and safe therapy for refractory non-infectious uveitis across all age-groups and etiologies. Early escalation to biologics may help arrest long-term cumulative inflammatory damage and preserve visual function by sustained inflammatory control."

Journal • Idiopathic Arthritis • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pediatrics • Rheumatology • Uveitis

Drug-Free Remission in Early Peripheral Spondyloarthritis, including Psoriatic Arthritis: 10-year follow-up from the CRESPA trial. (PubMed, Arthritis Rheumatol) - "Remission induction with golimumab in patients with early pSpA enables achievement of sustained clinical remission in the majority of patients with one-third of patients attaining drug-free remission. Strikingly, almost half of non-psoriatic pSpA remained in drug-free remission. These findings strongly suggest that early, intensive treatment has the potential to achieve long-term disease control, potentially leading to sustained drug-free remission in a subset of patients."

Journal • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Clinical Outcomes After TNF Inhibitor Initiation in Inflammatory Bowel Disease Patients With and Without Prior Risankizumab Exposure: A Propensity-Matched National Cohort Study (ACG 2026) - "Adults with UC or CD who initiated a TNFi (infliximab, adalimumab, or golimumab) after diagnosis were included during 2015-2025. The UC analysis included 100,000 controls and 65 patients with prior RISA; the CD analysis included 100,000 controls and 149 patients with prior RISA. After propensity score matching in UC, prior RISA exposure was not associated with the composite IBD outcome, ED visits, or IL-23 inhibitor use, but was associated with increased oral steroid receipt (IRR 2.64, 95% CI 1.52-4.60; p< 0.001). In CD, prior RISA exposure was associated with higher rates of the composite outcome (IRR 3.00, 95% CI 1.99-4.53; p< 0.001), ED visits (IRR 3.79, 95% CI 1.95-7.37; p< 0.001), inpatient visits (IRR 3.57, 95% CI 1.67-7.61; p=0.001), IV steroids (IRR 3.33, 95% CI 1.83-6.08; p< 0.001), and oral steroids (IRR 2.36, 95% CI 1.56-3.56; p< 0.001), while IBD surgery was not significantly different (Table 1)."

Clinical • Clinical data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Prevalence and Outcomes of Hormone Therapy Use Among Menopausal Women With Inflammatory Bowel Disease (ACG 2026) - "However, patients with CD prescribed systemic HT had higher oral prednisone use, while osteoporosis/fracture outcomes were lower among patients receiving systemic HT. Figure: 1-Systemic non-transdermal HRT included oral estradiol, conjugated estrogens, esterified estrogens, synthetic conjugated estrogens A and B, oral progesterone, oral medroxyprogesterone, conjugated estrogens/bazedoxifene (Duavee), estradiol acetate vaginal ring (Femring), and norethindrone acetate/ethinyl estradiol (Femhrt). 2-Systemic transdermal HRT included estradiol/norethindrone acetate transdermal patch (CombiPatch), estradiol/levonorgestrel transdermal patch (Climara Pro), estradiol transdermal patches (Alora, Climara, Dotti, Estraderm, Lyllana, Minivelle, Vivelle-Dot), estradiol transdermal gel (EstroGel, Divigel), and estradiol transdermal spray (Evamist). 3-Local estrogen therapy included low-dose vaginal estradiol formulations (Estring, Imvexxy, Vagifem, and Yuvafem) and vaginal conjugated..."

Clinical • Cardiovascular • Coronary Artery Disease • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pulmonary Embolism • Respiratory Diseases • Ulcerative Colitis

Perioperative Safety Profile of IBD Medications: A Comparative Study of Real World Pharmacovigilance Data (ACG 2026) - "Golimumab showed elevated UC sepsis (1.88), whereas Adalimumab and Certolizumab showed lower CD sepsis (0.54, 0.27) and Adalimumab lower DVT and PE in both indications. Vedolizumab showed elevated UC DVT and PE (~1.5); natalizumab elevated CD PE (2.30); ustekinumab an isolated UC ileus signal (14.15)... Thiopurines and Methotrexate showed the most consistent signals across both indications: elevated ROR for sepsis (Azathioprine UC: ROR 2.03, CD: 1.85; Mercaptopurine UC: 2.64, CD: 2.04; Methotrexate UC: 1.57), DVT (Methotrexate UC 4.15, CD 2.33; Azathioprine CD 2.23, Mercaptopurine UC 2.29), and PE (Methotrexate UC 1.96; Azathioprine CD 1.84). Azathioprine UC also showed elevated anastomotic leak (7.15). Among anti-TNFs, infliximab showed elevated CD sepsis (2.12), DVT (1.90), and PE (1.82), as well as UC DVT (1.32)."

Adverse events • Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Septic Shock • Ulcerative Colitis

Dual Biologic Therapy in a Pregnant Patient With Crohn's Disease and Axial Spondyloarthritis (ACG 2026) - "She had previous non-response to mesalamine, mercaptopurine, certolizumab pegol, adalimumab, infliximab, and upadacitinib, as well as combination therapy with upadacitinib and vedolizumab. She then achieved clinical remission with a combination of risankizumab and golimumab...Recent randomized trials showed improved rates of clinical remission in patients with ulcerative colitis and Crohnâs disease treated with dual therapy with guselkumab and golimumab compared to monotherapy...Data from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes (PIANO) registry has shown no increased risk of pregnancy complications in patients treated with anti-TNF medications, immunomodulators, TNF/immunomodulator combination therapy, vedolizumab, and ustekinumab in patients with IBD. This case highlights emerging therapeutic strategies and the importance of patient centered multidisciplinary care for optimal pregnancy outcomes."

Clinical • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis • CRP

Sustained Clinical and Endoscopic Improvements With up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderate to Severe Ulcerative Colitis Regardless of the Number of Prior Advanced Therapy Exposures (ACG 2026) - "AT included approved biologics for UC (infliximab, adalimumab, golimumab, ustekinumab, and/or vedolizumab), approved Janus kinase inhibitors for UC (tofacitinib, filgotinib, upadacitinib), and/or ozanimod. At induction baseline, among the 1003 pts included in the AO analysis, 29.4% (N=295) were AT-naïve; 29.4% (N=295) and 41.2% (N=418) had previously experienced 1 and >1 AT, respectively. Among the RZB180 and RZB360 groups, rates of CR (per AMS or PAMS) generally remained stable at OLE W0 and 96, regardless of the number of prior AT exposures, per AO analysis. Rates of endoscopic improvement and remission were sustained, regardless of the number of prior AT exposures, per AO analysis."

Clinical • Metastases • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. (PubMed, Front Pharmacol) - "TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies;..."

Journal • Review • Ankylosing Spondylitis • Back Pain • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Pain • Ocular Inflammation • Oncology • Ophthalmology • Pain • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis • Uveitis • IL17A

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Efficacy of Risankizumab Versus Other Advanced Therapies for Moderate to Severe Ulcerative Colitis in Advanced Therapy Naïve Populations: A Bayesian Network Meta-Analysis (ACG 2026) - " This NMA utilized published data from phase 3 randomized controlled trials of the following FDA-approved first-line ATs for moderate to severe UC: RZB, guselkumab (GUS), mirikizumab (MIR), ustekinumab (UST), vedolizumab (VDZ), golimumab (GOL), infliximab (IFX), adalimumab (ADA), etrasimod (ETR), and ozanimod (OZA). ITT efficacy rates of clinical remission and endoscopic improvement were highest for RZB (1200 mg x 360 mg) ( Figure ). GUS, MIR, and RZB (1200 mg x 180 mg) had the highest ITT rates for clinical response. In the Induction NMA, RZB demonstrated the highest odds ratio (OR [95% credible interval]) vs PBO for clinical response (5.12 [3.29-7.94]) and endoscopic improvement (5.32 [3.03-9.68])."

Metastases • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis • Ulcerative Colitis

Clinical Outcomes After TNF Inhibitor Initiation in Patients With Inflammatory Bowel Disease and Prior Ustekinumab Exposure (ACG 2026) - "Adults with UC or CD who initiated a TNFi of infliximab, adalimumab, or golimumab were included. The UC cohort included 1,888 prior ustekinumab-exposed patients and 98,275 controls; the CD cohort included 3,521 exposed patients and 100,000 controls. Observed 1-year composite outcome rates were higher in exposed versus control patients for UC (26.43% vs 20.71%) and CD (32.09% vs 23.52%). After propensity matching, prior ustekinumab exposure was associated with higher composite outcome rates in UC (IRR 1.54, 95% CI 1.35-1.76; p< 0.001) and CD (IRR 1.38, 95% CI 1.26-1.50; p< 0.001)."

Clinical • Clinical data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Herpes Zoster Infection as an Adverse Reaction to Treatments for Ulcerative Colitis: A Review of Reports to the FDA Adverse Events Reporting System (FAERS) (ACG 2026) - "Reports of ADRs of all FDA approved UC therapies including mesalamine, sulfasalazine, balsalazide, olsalazine, methotrexate, azathioprine, 6-mercaptopurine, infliximab, adalimumab, certolizumab, golimumab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, ozanimod, etrasimod, tofacitinib, and upadacitinib along with combination infliximab with methotrexate, infliximab with azathioprine, adalimumab with azathioprine, and golimumab with azathioprine were reviewed. Table 1 displays the total FAERS reports of ADRs and reported HZ infection in patients treated for UC. The JAK inhibitor tofacitinib showed increased risk of HZ with 58 total reports (ROR 2.79). In addition, methotrexate (ROR 1.83), azathioprine (ROR 1.74), 6-mercaptopurine (ROR 2.4), infliximab (ROR 2.49), and combination therapies of infliximab with methotrexate (ROR 2.61) and infliximab with azathioprine (ROR 2.91) demonstrated increased risk."

Adverse events • Review • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster • ROR1

Drug-Induced Pancreatitis Across UC Therapeutics: A Real-World Pharmacovigilance Study (ACG 2026) - " FAERS was queried for reports of pancreatitis associated with UC treatments including immunomodulators (azathioprine, mercaptopurine, methotrexate, tacrolimus), 5-aminosalicylates (mesalamine, balsalazide, olsalazine, sulfasalazine), anti-TNF agents (adalimumab, infliximab, golimumab, certolizumab pegol), integrin inhibitors (vedolizumab, natalizumab), IL-12/23 inhibitors (ustekinumab, risankizumab, guselkumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod, etrasimod). 83,046 reports with 612 pancreatitis cases were analyzed. Significantly elevated risk was observed with azathioprine (ROR 4.38, 95% CI 3.56-5.38), mesalamine (ROR 2.32, 95% CI 1.87-2.89), and infliximab (ROR 1.47, 95% CI 1.21-1.80; all p< 0.0001). Reduced risk was identified with adalimumab (ROR 0.60, 95% CI 0.49-0.74), vedolizumab (ROR 0.69, 95% CI 0.51-0.93), and ustekinumab (ROR 0.13, 95% CI 0.02-0.94)."

Adverse events • Clinical • Real-world • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pancreatitis • Ulcerative Colitis • IL12A • ROR1

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events (clinicaltrials.gov) - P4 | N=32 | Completed | Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Paradoxical Psoriatic Alopecia Induced by Golimumab: Diagnostic Clues from Trichoscopy and Histopathology (EADV 2026) - No abstract available

Alopecia • Immunology